Legal Research

This Week?s Biotech Highlights

By Jeremy Grushcow

I spent a good chunk of this past week at BioFinance in Toronto, where I spoke about public market strategies for cleantech and blogged about the keynote address by Scott Gottlieb, an ex-FDA official now at the American Enterprise Institute, who talked about follow-on biologics, comparative effectiveness, and the regulatory environment at the FDA.

In the real world, Swine Flu continued to spread but turned out not to be as virulent as we first thought, at least for now.  We also learned that the party is over for medical imaging in the U.S. and for basic research in the U.K.  But the party is just getting started for Teralys Capital, with $700 million to invest in Cleantech, Biotech, and Infotech, and for early screening for breast cancer using MRI, which may be as effective as mammography without the radiation.

Stay tuned this week for more trends, more deals and (sadly) more swine flu at the Cross-Border Biotech Blog.

Full post as published by Slaw.ca on May 04, 2009 (boomark / email).